Literature DB >> 24092875

Reclassification of European patients' cardiovascular risk using the updated Systematic Coronary Risk Evaluation algorithm.

Julian P Halcox1, Florence Tubach2, Ogün Sazova3, Stephen Sweet4, Jesús Medina5.   

Abstract

Data from the European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice (EURIKA; ClinicalTrials.gov; NCT00882336) was used to assess the proportions of patients aged 50-65 years free of diabetes and not receiving lipid-lowering therapy (LLT) considered to be at low (<1%), intermediate (1% to <5%) and high (≥5%) 10-year risk of cardiovascular mortality according to the Systematic Coronary Risk Evaluation (SCORE) algorithm and the updated algorithm that considers patients' total cholesterol and high-density lipoprotein cholesterol (HDL-C) levels as independent variables (SCORE-HDL). Of 2321 patients analysed, 19.3%, 60.7% and 20.0% were considered to be at low, intermediate and high cardiovascular risk respectively according to SCORE, and 25.7%, 57.2% and 17.1% respectively according to SCORE-HDL. Thus, there was an overall trend towards reclassification from higher to lower risk categories when SCORE-HDL was compared with SCORE. © The European Society of Cardiology 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  Cardiology; estimation techniques; risk factors

Mesh:

Substances:

Year:  2013        PMID: 24092875     DOI: 10.1177/2047487313507680

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


  3 in total

Review 1.  Epidemiological studies of CHD and the evolution of preventive cardiology.

Authors:  Nathan D Wong
Journal:  Nat Rev Cardiol       Date:  2014-03-25       Impact factor: 32.419

Review 2.  Early Vascular Ageing - A Concept in Development.

Authors:  Peter M Nilsson
Journal:  Eur Endocrinol       Date:  2015-04-11

3.  The Management of Non-Dialysis-Dependent Chronic Kidney Disease in Primary Care.

Authors:  Gesine Weckmann; Jean-François Chenot; Sylvia Stracke
Journal:  Dtsch Arztebl Int       Date:  2020-10-30       Impact factor: 5.594

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.